Precede Biosciences closed an $83.5 million Series B and a $20 million credit facility to expand its liquid‑biopsy platform and capacity for pharma collaborations. Investors include Labcorp Venture Fund, UPMC Enterprises, and Illumina Ventures; strategic backers include Bristol Myers Squibb and Lilly Asia Ventures. Precede said the capital will fund scaling of assays that measure genome‑wide cancer surface protein expression from blood and support partnerships across ~30 drug programs. CEO Rehan Verjee cited growing demand from pharma for assays that characterize response and resistance to radiopharmaceuticals, ADCs and other modalities. The financing highlights ongoing commercial demand from drug developers for advanced peripheral biomarkers to support trial enrollment, mechanism‑of‑action studies, and adaptive development strategies.